December 2024

New Meningioma model in development in CTF Preclinical Hub Unlocks Opportunities for NF2-SWN Brain Tumor Therapies

We're proud to announce that the CTF Preclinical Hub is funding the development of a new meningioma model at the University of Plymouth. This project will advance research into NF2-related schwannomatosis brain tumors, creating opportunities for preclinical testing that could one day improve treatment options.

This collaboration with the University of Plymouth Brain Tumour Research Centre of Excellence marks an important step in expanding the foundation for NF research and better outcomes for patients.

Click below to learn more about this initiative.

Read More
story2

NF News Winter 2024 is Available Now

Read the Winter 2024 newsletter to learn how we’re advancing the fight to end NF:
• Breakthroughs in NF drug development and clinical trials
• Promising findings from AI-driven drug discovery and biomarker research
• Highlights from events uniting the NF community to drive progress
• Ways you can help accelerate progress for NF patients
Read Online
story3

2025 NF Summit Registration is Now Open

Pack your bags for Washington, DC, June 19-21, 2025, and join us for CTF's annual patient and family conference! This year’s NF Summit features interactive workshops, engaging sessions, and plenty of opportunities to connect with the NF community. Session topics will cover clinical care in all forms of NF, quality of life and self-advocacy, and patient engagement. Scholarships are available - apply by January 6, 2025.
Learn More

From Discovery to Impact: How Collaboration Unlocked Brigatinib for NF2-Related Schwannomatosis

A pivotal chapter in the story of drug discovery for NF2-related schwannomatosis has been written – both figuratively and literally – with a new publication highlighting the critical role of collaboration in the journey of Brigatinib, a drug now offering hope to patients with this rare condition. The chapter, co-authored by a multidisciplinary team of researchers including Dr. Annette Bakker, CEO of the Children’s Tumor Foundation, underscores the groundbreaking work that made Brigatinib a reality for NF2-SWN.

Read More
Facebook
Twitter
Instagram
YouTube
LinkedIn
CTF NEWSFEED   |  DONATE